Skip to main content

VESICULAS EXTRACELULARES COMO PORTADORES DE PROTEINAS PARA MODULAR EL FENOTIPO DINAMICO DE LAS CELULAS MADRE DEL CANCER Y EL ACONDICIONAMIENTO DE NICHO METASTÁSICO A TRAVES DE LA COMUNICACION CELULAR.

PI20/01474

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON (VHIR)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Extracellular Vesicles as Drug Delivery Systems in Cancer

  • Hernández Oller, Laia|||0000-0003-4116-6595
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Andrade, Fernanda|||0000-0002-4947-2346
  • Rafael, Diana|||0000-0003-3180-3028
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Gener, Petra|||0000-0002-2250-570X
  • Schwartz, Simon|||0000-0001-8297-7971
Within tumors, Cancer Stem Cell (CSC) subpopulation has an important role in maintaining growth and dissemination while preserving high resistance against current treatments. It has been shown that, when CSCs are eliminated, the surrounding Differentiated Cancer Cells (DCCs) may reverse their phenotype and gain CSC-like features to preserve tumor progression and ensure tumor survival. This strongly suggests the existence of paracrine communication within tumor cells. It is evidenced that the molecular crosstalk is at least partly mediated by Extracellular Vesicles (EVs), which are cell-derived membranous nanoparticles that contain and transport complex molecules that can affect and modify the biological behavior of distal cells and their molecular background. This ability of directional transport of small molecules prospects EVs as natural Drug Delivery Systems (DDS). EVs present inherent homing abilities and are less immunogenic than synthetic nanoparticles, in general. Currently, strong efforts are focused into the development and improvement of EV-based DDS. Even though EV-DDS have already reached early phases in clinical trials, their clinical application is still far from commercialization since protocols for EVs loading, modification and isolation need to be standardized for large-scale production. Here, we summarized recent knowledge regarding the use of EVs as natural DDS against CSCs and cancer resistance.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Extracellular vesicles secreted by triple-negative breast cancer stem cells trigger premetastatic niche remodeling and metastatic growth in the lungs

  • González-Callejo, Patricia|||0000-0003-2963-4878
  • Gener, Petra|||0000-0002-2250-570X
  • Díaz Riascos, Zamira Vanessa|||0000-0003-1595-618X
  • Conti, Sefora|||0000-0002-0616-0692
  • Cámara-Sánchez, Patricia|||0000-0003-1958-9735
  • Riera Brillas, Roger|||0000-0001-9406-597X
  • Mancilla, Sandra|||0000-0002-9681-3588
  • García-Gabilondo, Miguel|||0000-0002-2015-2621
  • Peg, Vicente|||0000-0002-5203-6166
  • Arango, Diego|||0000-0003-2953-3284
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Labernadie, Anna|||0000-0001-5768-5088
  • Trepat, Xavier|||0000-0002-7621-5214
  • Albertazzi, Lorenzo|||0000-0002-6837-0812
  • Schwartz, Simon|||0000-0001-8297-7971
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Abasolo, Ibane|||0000-0001-5970-6276
Tumor secreted extracellular vesicles (EVs) are potent intercellular signaling platforms. They are responsible for the accommodation of the premetastatic niche (PMN) to support cancer cell engraftment and metastatic growth. However, complex cancer cell composition within the tumor increases also the heterogeneity among cancer secreted EVs subsets, a functional diversity that has been poorly explored. This phenomenon is particularly relevant in highly plastic and heterogenous triple-negative breast cancer (TNBC), in which a significant representation of malignant cancer stem cells (CSCs) is displayed. Herein, we selectively isolated and characterized EVs from CSC or differentiated cancer cells (DCC; EVs and EVs, respectively) from the MDA-MB-231 TNBC cell line. Our results showed that EVs and EVs contain distinct bioactive cargos and therefore elicit a differential effect on stromal cells in the TME. Specifically, EVs activated secretory cancer associated fibroblasts (CAFs), triggering IL-6/IL-8 signaling and sustaining CSC phenotype maintenance. Complementarily, EVs promoted the activation of α-SMA+ myofibroblastic CAFs subpopulations and increased the endothelial remodeling, enhancing the invasive potential of TNBC cells in vitro and in vivo. In addition, solely the EVs mediated signaling prompted the transformation of healthy lungs into receptive niches able to support metastatic growth of breast cancer cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics

  • Ulldemolins, Anna|||0000-0001-8825-9436
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Andrade, Fernanda|||0000-0002-4947-2346
  • Rafael, Diana|||0000-0003-3180-3028
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Gener, Petra|||0000-0002-2250-570X
  • Schwartz, Simon|||0000-0001-8297-7971
Advanced cancer is still considered an incurable disease because of its metastatic spread to distal organs and progressive gain of chemoresistance. Even though considerable treatment progress and more effective therapies have been achieved over the past years, recurrence in the long-term and undesired side effects are still the main drawbacks of current clinical protocols. Moreover, a majority of chemotherapeutic drugs are highly hydrophobic and need to be diluted in organic solvents, which cause high toxicity, in order to reach effective therapeutic dose. These limitations of conventional cancer therapies prompted the use of nanomedicine, the medical application of nanotechnology, to provide more effective and safer cancer treatment. Potential of nanomedicines to overcome resistance, ameliorate solubility, improve pharmacological profile, and reduce adverse effects of chemotherapeutical drugs is thus highly regarded. Their use in the clinical setting has increased over the last decade. Among the various existing nanosystems, nanoparticles have the ability to transform conventional medicine by reducing the adverse effects and providing a controlled release of therapeutic agents. Also, their small size facilitates the intracellular uptake. Here, we provide a closer review of clinical prospects and mechanisms of action of nanomedicines to overcome drug resistance. The significance of specific targeting towards cancer cells is debated as well.